HOME >> BIOLOGY >> NEWS
Tumor response may not be best measure of efficacy in non-small cell lung cancer treatment

Researchers typically evaluate the effectiveness of a new cancer treatment by looking at how tumors respond to it. But in the case of advanced non-small cell lung cancer, there may be a better way to assess effectiveness.

A new Southwest Oncology Group study led by a team of UC Davis Cancer Center researchers suggests that an alternative measurement "disease control rate" may be a more powerful predictor of survival than tumor shrinkage. The research was presented today at the annual meeting of the American Society of Clinical Oncology in Atlanta.

"If validated, this 'early look' statistical measure could enhance efficacy assessment, with broad implications for the design of future cancer clinical trials for advanced non-small cell lung cancer," said Primo N. Lara, Jr., associate professor of hematology and oncology at UC Davis Cancer Center and lead author of the new study.

Lara and his colleagues defined the disease control rate as the percentage of patients who have a partial or complete response to an investigational treatment plus those whose disease stabilizes.

"In the past, we have used the complete response rate plus the partial response rate, or CR + PR, as our sole efficacy measure," Lara said. "The disease control rate, DCR, is the complete response rate plus the partial response rate plus the rate of patients with stabilized disease, or DCR = CR + PR + SD. This measure may better predict how a new drug will affect survival."

In their study, the investigators pooled data from 984 patients with advanced non-small cell lung cancer who participated in three randomized SWOG trials of platinum-based chemotherapy regimens.

Of the 886 patients who were alive two months after beginning treatment, 62 percent had stable disease, meaning their cancer had not progressed since entering the clinical trial. Another 19 percent had a complete or partial response, meaning their tumors had disappeared or reduced in size. Ad
'"/>

Contact: Claudia Morain
claudia.morain@ucdmc.ucdavis.edu
916-734-9023
University of California, Davis - Health System
5-Jun-2006


Page: 1 2

Related biology news :

1. Tumor painting revolutionizes fight against cancer
2. Tumor vessels identified by unique molecular markers
3. Tumors stopped from spreading to new sites
4. Chest Tumors -- Prevention, treatment and future perspectives
5. Tumor cells evade death through autophagy
6. Tumor-free breast tissue can have precancerous changes
7. Tumor-suppressor gene is critical for placenta development
8. Tumor cells that border normal tissue are told to leave
9. Tumor suppressor activity of PTEN
10. Tumor individuality useful for guiding rational chemotherapeutic decisions
11. MIT model could predict cells response to drugs

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/4/2017)... , April 4, 2017   EyeLock LLC , ... that the United States Patent and Trademark Office (USPTO) ... covers the linking of an iris image with a ... and represents the company,s 45 th issued patent. ... is very timely given the multi-modal biometric capabilities that ...
(Date:3/29/2017)... -- higi, the health IT company that operates the largest ... , today announced a Series B investment from BlueCross ... new investment and acquisition accelerates higi,s strategy to create ... health activities through the collection and workflow integration of ... and secures data today on behalf of over 36 ...
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based and ... 2022", published by MarketsandMarkets, the market is expected to be worth USD 18.98 ... Continue Reading ... ...      ...
Breaking Biology News(10 mins):
(Date:8/17/2017)... Springs, FL (PRWEB) , ... August 17, 2017 ... ... announced that the stock market news outlet had provided a research update on ... company's nasally administered TRT product. , According to Soulstring, prescription rates for Natesto® ...
(Date:8/16/2017)... Yorba Linda, Ca (PRWEB) , ... August 16, ... ... resist treatment by changing into a different cell type. Many treatments for specific ... tissue. A prominent example of targeted treatment is androgen deprivation therapy for advanced ...
(Date:8/16/2017)... 16, 2017  This year,s edition of the Inc. 5000 features a ... workforce solutions, has made the list for the third year in a ... fastest-growing private companies based on a set of quantitative metrics. In addition, ... fastest-growing companies in the Bay State . ... Inc. 5000 ...
(Date:8/15/2017)... (PRWEB) , ... August 15, 2017 , ... ... graphene biosensors that accelerate pharmaceutical and biotherapeutics development, announces the launch of the ... of steps needed to gain kinetic binding data for a wide range of ...
Breaking Biology Technology:
Cached News: